Altimmune to Participate at Two Upcoming Investor Conferences

Rhea-AI Summary

Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, has announced its participation in two upcoming investor conferences. Management will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, with a fireside chat at 10:00 AM ET, and the Jefferies Global Healthcare Conference on June 4, 2025, with a fireside chat at 9:55 AM ET. Both events will take place in New York, and webcasts will be available on Altimmune's website. The company will also be available for one-on-one meetings during these conferences.

News Market Reaction – ALT

-1.04%

1 alert

-1.04% News Effect

On the day this news was published, ALT declined 1.04%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:

• H.C. Wainwright 3^rd Annual BioConnect Investor Conference (New York, NY)
  Tuesday, May 20, 2025
  Fireside Chat at 10:00 a.m. Eastern Time

• Jefferies Global Healthcare Conference (New York, NY)
  Wednesday, June 4, 2025
  Fireside Chat at 9:55 a.m. Eastern Time

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Media Contact:
Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
Jake.robison@inizioevoke.com

This press release was published by a CLEAR® Verified individual.

FAQ

When is Altimmune (ALT) presenting at the H.C. Wainwright BioConnect Conference 2025?

Altimmune will present at the H.C. Wainwright BioConnect Conference on Tuesday, May 20, 2025, at 10:00 AM Eastern Time in New York.

What time is Altimmune's presentation at the Jefferies Global Healthcare Conference 2025?

Altimmune will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:55 AM Eastern Time in New York.

Where can I watch Altimmune's (ALT) investor conference presentations?

The conference sessions will be webcast and can be accessed through the Events section of Altimmune's website.

What type of company is Altimmune (ALT)?

Altimmune is a late clinical-stage biopharmaceutical company that develops novel peptide-based therapeutics for liver and cardiometabolic diseases.